OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALGEN57

Genoway SA

Biotechnology & Medical ResearchVerified

Genoway's capital structure is characterized by a basic and diluted share count of 12,115,177 shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity position remains unassessed due to the absence of balance-sheet inputs and lack of going-concern language in source documents. Profitability and return metrics are not available for Genoway, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This absence of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the diversification of Genoway's revenue streams or its exposure to specific markets. Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue projections. The absence of historical revenue data further limits the ability to assess the company's growth potential. Risk factors include the unassessed liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the lack of detailed capital structure data means that potential dilution sources cannot be fully evaluated. Recent events and filings do not provide additional insights into the company's operations or strategic direction. The absence of transcripts or detailed disclosures limits the ability to assess management's guidance or investor sentiment.

30-day price · ALGEN(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGenoway SA
TickerALGEN.PA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Genoway SA is a biotechnology company focused on the development of innovative diagnostic solutions for the healthcare industry.

Classification. Genoway is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Genoway's capital structure is characterized by a basic and diluted share count of 12,115,177 shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity position remains unassessed due to the absence of balance-sheet inputs and lack of going-concern language in source documents. Profitability and return metrics are not available for Genoway, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This absence of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the diversification of Genoway's revenue streams or its exposure to specific markets. Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue projections. The absence of historical revenue data further limits the ability to assess the company's growth potential. Risk factors include the unassessed liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the lack of detailed capital structure data means that potential dilution sources cannot be fully evaluated. Recent events and filings do not provide additional insights into the company's operations or strategic direction. The absence of transcripts or detailed disclosures limits the ability to assess management's guidance or investor sentiment.
Key takeaways
  • Genoway operates in the healthcare diagnostics segment with a focus on biotechnology.
  • The company's liquidity position is unassessed, raising concerns about short-term financial stability.
  • No profitability metrics are available, making it difficult to evaluate performance against industry standards.
  • Revenue concentration and geographic exposure are not disclosed, limiting visibility into business diversification.
  • Analysts have issued a strong buy recommendation with a mean price target of 4.40 EUR.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$14.0M-$69.4k-$322.6k-$674.0k
FY-3$17.1M$1.4M$777.8k$1.2M
FY-2$20.0M$2.1M$1.6M$2.2M
FY-1$22.1M$2.1M$1.8M$2.0M
FY0$21.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$32.7M$14.6M$0.00
FY-3$32.9M$15.4M$0.00
FY-2$31.8M$17.4M$0.00
FY-1$31.8M$18.6M$0.00
FY0
PeriodOCFCapExFCFSBC
FY-4-$561.3k-$2.3M-$674.0k
FY-3$2.4M-$1.9M$1.2M
FY-2$3.1M-$1.8M$2.2M
FY-1$5.4M-$2.4M$2.0M
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricALGENActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Observations
IR observations
Mean price target4.40 EUR
Median price target4.40 EUR
High price target4.40 EUR
Low price target4.40 EUR
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.00 EUR
Mean revenue estimate24,100,000 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 04:12 UTC#eff669b5
Market quoteclose EUR 2.50 · shares 0.01B diluted
no public URL
2026-05-09 04:12 UTC#559305dc
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:52 UTCJob: c1503050